Pharmacotherapy for end-stage coronary artery disease

Author： Sodha Neel R   Chu Louis M   Boodhwani Munir   Sellke Frank W  

Publisher： Informa Healthcare

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.11, Iss.2, 2010-02, pp. : 207-213

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Epidemiology of end-stage renal disease

By Roderick Paul  

Clinical Medicine, Vol. 2, Iss. 3, 2002-05 ,pp. : 200-204

Royal College Of Physicians

Access to resources Recommend Favorite

Emerging drugs for complications of end-stage liver disease

By Dowman Joanna K   Holt Andrew P   Newsome Philip N   Adams David H  

Expert Opinion on Emerging Drugs, Vol. 13, Iss. 1, 2008-03 ,pp. : 159-174

Informa Healthcare

Access to resources Recommend Favorite

Anorexia in end-stage renal disease: pathophysiology and treatment

By Alvarez Vicente   Diéz Juan Jose   Aguilera Abelardo   Selgas Rafael   Codoceo Rosa   Bajo Maria A  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 11, 2001-11 ,pp. : 1825-1838

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics of Rosiglitazone in Patients with End-stage Renal Disease

By Thompson-Culkin K   Zussman B   Miller AK   Freed MI  

The Journal of International Medical Research, Vol. 30, Iss. 4, 2002-07 ,pp. : 391-399

Field House Publishing

Access to resources Recommend Favorite

Approach to the management of end-stage renal disease

By Rodger R Stuart C  

Clinical Medicine, Vol. 12, Iss. 5, 2012-10 ,pp. : 472-475

Royal College Of Physicians

Access to resources Recommend Favorite